Swiss National Bank Immunovant, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Immunovant, Inc. stock. As of the latest transaction made, Swiss National Bank holds 99,600 shares of IMVT stock, worth $2.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,600

Previous 99,600 -0.0%

Holding current value

$2.74 Million

Previous $2.63 Million 4.18%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$31.31 - $44.19 $923,645 - $1.3 Million	-29,500 Reduced 22.85%	99,600 $4.2 Million
Q3 2023 Nov 08, 2023	BUY	$18.55 - $39.96 $291,235 - $627,372	15,700 Added 13.84%	129,100 $4.96 Million
Q2 2023 Aug 09, 2023	BUY	$14.2 - $23.75 $423,160 - $707,750	29,800 Added 35.65%	113,400 $2.15 Million
Q1 2023 May 10, 2023	SELL	$15.27 - $19.72 $151,173 - $195,228	-9,900 Reduced 10.59%	83,600 $1.3 Million
Q4 2022 Feb 08, 2023	SELL	$6.59 - $17.75 $10,544 - $28,400	-1,600 Reduced 1.68%	93,500 $1.66 Million
Q1 2022 May 09, 2022	BUY	$5.06 - $8.77 $32,383 - $56,128	6,400 Added 7.22%	95,100 $524,000
Q4 2021 Feb 08, 2022	BUY	$7.33 - $9.32 $96,023 - $122,092	13,100 Added 17.33%	88,700 $756,000
Q2 2021 Aug 06, 2021	SELL	$9.4 - $16.85 $17,860 - $32,015	-1,900 Reduced 2.45%	75,600 $799,000
Q4 2020 Feb 05, 2021	BUY	$36.36 - $52.71 $119,988 - $173,943	3,300 Added 4.45%	77,500 $3.58 Million
Q3 2020 Nov 09, 2020	BUY	$22.61 - $38.9 $510,986 - $879,140	22,600 Added 43.8%	74,200 $2.61 Million
Q2 2020 Aug 05, 2020	BUY	$13.87 - $28.44 $715,692 - $1.47 Million	51,600 New	51,600 $1.26 Million

Others Institutions Holding IMVT

# of Institutions

212

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Immunovant, Inc. Transaction History